文献速递脊柱关节炎

培塞利珠单抗治疗非放射学中轴型脊柱关节炎的长期临床结局:按基线MRI和CRP状态分层

Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status.
PubMed 文献 · RMD Open · 2024-05-09

C-axSpAnd 3期多中心研究的事后分析,评估培塞利珠单抗治疗活动性非放射学中轴型脊柱关节炎患者至第156周的疗效,按基线MRI和CRP状态分层。各亚组从第0周均有大幅改善,第52周至第156周疗效总体维持,MRI+/CRP+患者应答数值上更高或相当。

要点

  • 第156周ASDAS-MI(观察病例):MRI+/CRP+ 73.1%,MRI-/CRP+ 52.2%,MRI+/CRP- 30.4%。
  • 第156周ASAS40:MRI+/CRP+ 76.9%,MRI-/CRP+ 62.5%,MRI+/CRP- 65.2%。
  • 三个亚组第52周至第156周疗效总体维持,MRI+/CRP+应答数值上更高或相当。

核心结论

  • 在具有客观炎症征象的非放射学中轴型脊柱关节炎患者中,MRI+/CRP+、MRI-/CRP+和MRI+/CRP-三个亚组治疗1年后获得的长期临床结局在3年时总体维持。

研究设计与样本

  • C-axSpAnd(NCT02552212)为3期多中心研究,评估培塞利珠单抗治疗存在MRI活动性骶髂关节炎和/或CRP升高的活动性非放射学中轴型脊柱关节炎患者。
  • 本分析为事后分析,报告C-axSpAnd至第156周的疗效结局,包括第52周至第156周的安全性随访扩展期,按第0周MRI和CRP状态分层(MRI+/CRP-、MRI-/CRP+和MRI+/CRP+)。

主要发现

  • 所有结局指标(包括ASDAS-MI和ASAS40)在安全性随访扩展期患者中从第52周至第156周总体维持。
  • 第52周和第156周时MRI+/CRP+患者的应答数值上高于或相当于MRI-/CRP+和MRI+/CRP-患者,但三个亚组从第0周均表现出大幅改善。
  • 在培塞利珠单抗随机化患者中,第156周ASDAS-MI(观察病例):MRI+/CRP+ 73.1%,MRI-/CRP+ 52.2%,MRI+/CRP- 30.4%。
  • 在培塞利珠单抗随机化患者中,第156周ASAS40:MRI+/CRP+ 76.9%,MRI-/CRP+ 62.5%,MRI+/CRP- 65.2%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There is a paucity of data on long-term clinical responses in patients with non-radiographic axial spondyloarthritis (nr-axSpA) based on their baseline objective signs of inflammation such as MRI or C-reactive protein (CRP) levels. This study reports clinical outcomes up to 3 years of the C-axSpAnd trial, including safety follow-up extension (SFE) from Weeks 52 to 156, stratified by patients' baseline MRI and CRP status. METHODS: C-axSpAnd (NCT02552212) was a phase 3, multicentre study that evaluated certolizumab pegol (CZP) in patients with active nr-axSpA who had active sacroiliitis on MRI and/or elevated CRP. In this post hoc analysis, efficacy outcomes are reported to Week 156 of C-axSpAnd for patients stratified according to their MRI and CRP status at Week 0 (MRI+/CRP-, MRI-/CRP+ and MRI+/CRP+). RESULTS: Across all outcome measures, including major improvement in Ankylosing Spondylitis Disease Activity Score (ASDAS-MI) and Assessment of SpondyloArthritis international Society criteria ≥40% response (ASAS40), outcomes were generally sustained in SFE patients from Week 52 to Week 156. MRI+/CRP+ patients showed numerically higher or comparable responses relative to MRI-/CRP+ and MRI+/CRP- patients at Weeks 52 and 156; however, all three subgroups demonstrated substantial improvements from Week 0 (in CZP-randomised patients, ASDAS-MI at Week 156 [observed case]: MRI+/CRP+: 73.1%, MRI-/CRP+: 52.2%, MRI+/CRP-: 30.4%; ASAS40: MRI+/CRP+: 76.9%, MRI-/CRP+: 62.5%, MRI+/CRP-: 65.2%). CONCLUSIONS: In patients with nr-axSpA and objective signs of inflammation, long-term clinical outcomes achieved after 1 year were generally sustained at 3 years across MRI+/CRP+, MRI-/CRP+ and MRI+/CRP- subgroups.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Rudwaleit M, Deodhar A, Bauer L, et al. Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status. RMD Open. 2024. PMID: 38724259. doi:10.1136/rmdopen-2023-003884

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。